CONCLUSIONS
respiratory failure, hypoxaemia
RESPIRATORY FAILURE
In conclusion, we found no convincingly strong evidence for substantial HTE with higher (12 mg) versus lower (6 mg) doses of dexamethasone on days alive without life support or mortality at Day 90 in patients with COVID‐19 and severe hypoxaemia according to age, weight, number of comorbidities, category of respiratory failure or predicted risks of mortality.